Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes self‐harm Timing of outcome assessment: end of treatment (8 to 24… compared with placebo (very low certainty).
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Mood stabilisers may leads to lower attrition Timing of outcome assessment: end of treatment (32 days to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (very low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether antipsychotics changes non‐serious adverse events Timing of outcome assessment: end of… compared with placebo (very low certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Deliberate self‐harm · patients with borderline personality disorder
1 finding from 1 review
Core symptoms of autism · Children aged 6 to 18 years with ASD
1 finding from 1 review
Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD
Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).
1 finding from 1 review
Language · Children aged 6 to 18 years with ASD
1 finding from 1 review
Memory (specific cognitive function) · Children aged 6 to 18 years with ASD
1 finding from 1 review
Adaptive behaviour · Children aged 6 to 18 years with ASD
1 finding from 1 review
Hyperactivity · Children aged 6 to 18 years with ASD
1 finding from 1 review
Irritability · Children aged 6 to 18 years with ASD
1 finding from 1 review
Healthcare providers’ attitudes/beliefs towards IPV · physicians/doctors, medical staff, medical students, residents, nurses and nursing students, dentists and dental students, counsellors and…
1 finding from 1 review
Healthcare providers’ readiness to respond to/manage survivors of IPV · physicians/doctors, medical staff, medical students, residents, nurses and nursing students, dentists and dental students, counsellors and…
1 finding from 1 review
Healthcare providers knowledge or awareness about IPV · physicians/doctors, medical staff, medical students, residents, nurses and nursing students, dentists and dental students, counsellors and…
1 finding from 1 review